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Background: Asthma exacerbations are often induced by the common cold, which, in turn, can be alleviated by
vitamin C.
Objective: To investigate whether vitamin C administration influences common cold-induced asthma.
Methods: Systematic review and statistical analysis of the identified trials. Medline, Scopus and Cochrane Central
were searched for studies that give information on the effects of vitamin C on common cold-induced asthma. All
clinically relevant outcomes related to asthma were included in this review. The estimates of vitamin C effect and
their confidence intervals [CI] were calculated for the included studies.
Results: Three studies that were relevant for examining the role of vitamin C on common cold-induced asthma
were identified. The three studies had a total of 79 participants. Two studies were randomized double-blind
placebo-controlled trials. A study in Nigeria on asthmatics whose asthma attacks were precipitated by respiratory
infections found that 1 g/day vitamin C decreased the occurrence of asthma attacks by 78% (95% CI: 19% to 94%).
A cross-over study in former East-Germany on patients who had infection-related asthma found that 5 g/day vitamin C
decreased the proportion of participants who had bronchial hypersensitivity to histamine by 52 percentage points
(95% CI: 25 to 71). The third study did not use a placebo. Administration of a single dose of 1 gram of vitamin C to
Italian non-asthmatic common cold patients increased the provocative concentration of histamine (PC20) 3.2-fold
(95% CI: 2.0 to 5.1), but the vitamin C effect was significantly less when the same participants did not suffer from the
common cold.
Conclusions: The three reviewed studies differed substantially in their methods, settings and outcomes. Each of them
found benefits from the administration of vitamin C; either against asthma attacks or against bronchial hypersensitivity,
the latter of which is a characteristic of asthma. Given the evidence suggesting that vitamin C alleviates common cold
symptoms and the findings of this systematic review, it may be reasonable for asthmatic patients to test vitamin C on
an individual basis, if they have exacerbations of asthma caused by respiratory infections. More research on the role of
vitamin C on common cold-induced asthma is needed.
Keywords: Anti-asthmatic agents, Ascorbic acid, Asthma, Bronchial provocation tests, Bronchoconstriction, Common
cold, Forced expiratory flow rates, Histamine, Rhinovirus, Upper respiratory tract infectionsIntroduction
Moses Maimonides, a 12th-century physician, wrote about
asthma: “I conclude that this disorder starts with a
common cold, especially in the rainy season…” [1].
Consistent with this statement, recent prospective studies
have detected respiratory viruses in up to 80% of asthma
exacerbations of children and adults [1-5]. The severity ofCorrespondence: harri.hemila@helsinki.fi
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reproduction in any medium, provided the orthe cold in asthmatics within its first two days predicted
the subsequent severity of the asthma exacerbation [6].
The common cold may lead to a transient bronchial
hypersensitivity, which is one characteristic of asthma
[7-12]. Hypothetically, preventing or alleviating common
cold symptoms might reduce the incidence and severity of
asthma exacerbations caused by respiratory viruses.
Vitamin C was identified in the early 1900s, in the
search for the etiology of scurvy [13]. After its identifica-
tion, there was much interest in the effects of vitamin Chis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diseases is still undetermined. In placebo-controlled trials
1 g/day or more of vitamin C shortened the duration of
colds in adults by 8% and in children by 18% [14-17]. The
common cold studies did not examine the effect of
vitamin C on pulmonary functions, but two trials found a
greater effect on lower respiratory symptoms than on
upper respiratory symptoms. Elwood et al. found that
vitamin C significantly decreased the incidence of “chest
colds” (−18%; cough or other chest symptoms) but not
of “simple colds” (+1%; runny nose or sneezing) [18,19].
Anderson et al. found that vitamin C significantly decreased
the incidence of “throat colds” (−21%) but not of “nose
colds” (−2%) [18,20]. Furthermore, vitamin C prevented
pneumonia in three controlled trials with participants
under special conditions [17,21].
The use of vitamin C for treating asthma dates back to
the 1940s. A few physicians reported that vitamin C seemed
beneficial for some of their asthma patients, but other
physicians found no such improvements in their asthma
patients [22,23]. A recent meta-analysis of three random-
ized trials on vitamin C and exercise-induced bronchocon-
striction found that vitamin C halved the post-exercise
decline of forced expiratory volume in 1 second (FEV1),
which indicates that vitamin C has effects on some pheno-
types of asthma [24].
This study was motivated by the findings that asthma
exacerbations are often induced by the common cold,
which in turn is alleviated by vitamin C. The objective
of this systematic review was to summarize the evidence




Intervention studies, randomised and non-randomised,
and placebo-controlled and non-placebo-controlled, that
give information on the effect of vitamin C on common
cold-induced asthma and/or bronchial hypersensitivity
were included in this systematic review.
Types of participants
Studies on children and adults of either sex at any age
were eligible.
Types of interventions
The interventions considered were the oral or intravenous
administration of vitamin C (ascorbic acid or its salts) as a
single dose or as multiple doses for a period.
Outcomes
All clinically relevant outcomes related to asthma such
as the number of asthma exacerbations, the severity ofasthma, airway hypersensitivity and pulmonary functions
were included in this review.
Literature searches
Medline (OVID) was searched using terms: (exp Ascorbic
acid/ or ascorb*.mp) and (exp Asthma/ or asthma*.mp or
bronch*.mp) and (exp Common cold/ or exp Respiratory
Tract Infections/ or respiratory infect*.mp). Similar searches
were carried out via Scopus and the Cochrane Central
Register of Controlled Trials. No language restrictions were
used. The databases were searched from their inception to
September 2013. Studies that fulfilled the selection criteria
were included. The reference lists of the identified studies
and relevant review articles were screened for additional
references. Finally, a cited article search of the Web of
Science database was carried out to search for papers
that cited the trials identified in the primary search. See
Additional file 1 for the flow diagram of the literature
search.
Selection of studies and data extraction
Three studies that were relevant to the investigation of
the role of vitamin C on common cold-induced asthma
were identified (Tables 1 and 2). The data of the three
included trials were extracted and analyzed by this author
(see below and Additional files 2 and 3). Dr. Bucca was
contacted for the original data, but she no longer retained
those data. Dr. Bucca reported the histamine PC20 values
of their study as figures in two separate reports [25,26].
In the current study, the individual-level values were
measured from one of the figures [26]; see Additional
file 2 for the data extraction. The reconstructed data set
has the same means and gives the same F-statistics as
Bucca et al. reported; see Additional files 2 and 3.
Statistical analysis
In 1980, Anah et al. reported the cumulative incidence of
asthma attacks during the trial [27], which gives a rate ratio
(RR) = 0.22 (95% confidence interval [CI]: 0.09-0.47) using
the “poisson.test” program of the R-package [28]. However,
Anah and colleagues did not publish the individual level
data or standard deviations (SD) for the distribution of
asthma attacks and therefore the variance per mean
ratio could not be calculated (it is 1.0 for the Poisson
distribution). Nevertheless, they published partial descrip-
tions of the asthma attack distributions that were used to
generate more realistic over-dispersed Poisson-type distri-
butions for the treatment groups. The exact distribution of
the severe and moderate asthma attacks in the vitamin C
group could be inferred and thus the RR for severe and
moderate attacks involves fewer imputations than the RR
for all asthma attacks. The RRs and their 95% CIs were
then calculated by using the “glm.nb” program of the R
package, which fits the negative binomial regression model
Table 1 Characteristics of the included trials
Study Item Description
Anah et al. 1980 [27] Participants 41 asthmatic subjects attending an asthma clinic in Nigeria. All had had asthma for
at least 4 yrs. The participants had histories of increased asthma attacks during the
rainy season. In all cases their attacks were precipitated by respiratory infections, which
started with a sore throat and a dry cough. The trial was conducted during the rainy
season. Patients with bronchitis were excluded. 22 M, 19 F; age 15 to 46 y (mean 27 y);
22 vit C 19 placebo.
Duration 14 wk
Intervention 1 g/d vit C or a placebo for 14 wk.
Outcome Frequency of asthma attacks. “Severe attacks” indicate those that needed emergency
attendance at the hospital; “moderate attacks” those that necessitated the use of
inhalers more frequently, and “mild attacks” those that caused some increase in
wheezing and breathlessness.
Notes See calculations in Additional files 2 and 3.
Schertling et al. 1990 [30,31] Participants 29 Participants with a diagnosis of infection-related asthma in former East-Germany.
Patients with acute and serious purulent infections were excluded. 18 M, 11 F; age
18 to 60 y.
Duration Total duration 5 wk, composed of 2 periods of 2 wk intervention and a 1 wk washout
between them.
Intervention 5 g/d vit C or placebo for 1 wk before the histamine sensitivity test in the middle of
the 2 wk intervention. Washout 1 wk between the 2-wk intervention phases.
Outcomes 1) Sensitivity to histamine: positive result indicates that exposure to <1 μmol histamine
increased respiratory tract resistance by 50%. 2) Asthma symptom score, 3) PEF
Notes See calculations in Additional file 2. The histamine sensitivity data are reported for 23
participants. There is no description for the missing data.
Bucca et al. 1989 [25,26] Participants 9 members of hospital staff in Italy with a negative history of asthma and atopy. All
suffered from the common cold with cough on the first vit C test day, and all had
recovered on the second vit C test day 6 wk later. 5 M, 4 F; age 18 to 48 y (mean 29 y).
Duration Two study days separated by 6 wk.
Intervention Single dose 2 g of vit C.
Outcome PC20 was measured at baseline and 1 h after vit C administration on both study days.
Notes See calculations in Additional files 2 and 3.
Abbreviations:
PC20: Concentration of histamine needed for a 20% FEV1 decrease.
PEF: Peak Expiratory Flow.
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findings of the Anah study (Table 3) see Additional files 2
and 3 for the calculations.
In 1990, Schertling et al. reported the numbers of
participants who were sensitive to histamine on the
vitamin C and the placebo phases of a cross-over study
[30,31]. Bronchial hypersensitivity was defined as a
cumulative dose of <1 μmol histamine that caused a 50%
increase in respiratory tract resistance. In the current
study, the P-value for the difference in the proportions of
participants with bronchial hypersensitivity to histamine
between the vitamin C and the placebo phases was calcu-
lated from the discordant observations using the binomial
distribution. The 95% CI for the difference in the propor-
tions was calculated using the Agresti-Caffo method [32].
See Additional file 2 for the calculations. Schertling and
colleagues did not report the distribution for asthma
symptom scores or PEF values, but they reported theWilcoxon-test P-values for the vitamin C and the placebo
phase differences [30,31], which are shown in Table 3.
In 1989, Bucca et al. reported the histamine provocation
concentrations that caused a 20% decline in FEV1 level
(PC20) at baseline and at 1 hour after vitamin C adminis-
tration for two study days that were separated by a 6 week
interval [25,26]. On the first vitamin C test day, the
participants suffered from the common cold, and 6 weeks
later, on the second vitamin C test day, they had all
recovered. In the current study, the effect of vitamin C
was calculated as the difference in the log(PC20) levels
between the baseline and 1 hour after vitamin C
administration. A paired t-test was used to calculate
the P-value and the 95% CI in the log-scale was also
obtained. Thereafter the 95% CI was converted into
the ratio scale. The paired t-test of the log(PC20) values
was also used to calculate the interaction P-value
between the vitamin C effect and the presence of the
Table 2 Methodological characteristics of the included trials
Study Domain of interest Description
Anah et al. 1980 [27] Design Parallel-group trial.
Randomization Reported as a randomized trial, but the method of randomization
was not described.
Allocation concealment Not described, but double-blinding implies that allocation must
have been concealed.
Blinding of participants and personnel Reported as double-blind, which implies that participants and
personnel were blind; however, the persons who were blind are
not explicitly described.
Blinding of outcome assessment Reported as double-blind, which implies that outcome assessment
was blind; however, the persons who were blind are not explicitly
described.
Drop-outs No description of drop-outs.
Schertling et al. 1990 [30,31] Design Cross-over trial.
Randomization Reported as a randomized trial, but the method of randomization
was not described.
Allocation concealment Not described, but double-blinding implies that allocation must
have been concealed.
Blinding of participants and personnel Reported as double-blind, which implies that participants and
personnel were blind; however, the persons who were blind are
not explicitly described.
Blinding of outcome assessment Reported as double-blind, which implies that outcome assessment
was blind; however, the persons who were blind are not explicitly
described.
Drop-outs Total number of participants was 29, but histamine sensitivity is
reported for 23 participants. The reasons for the 6 missing participants
are not given.
Bucca et al. 1989 [25,26] Design Self-controlled trial. Two series of histamine challenge tests were
done before and after vit C. The first series was carried out when
the participants suffered from the common cold, and the second
series was carried out 6 wk later after the participants had recovered.
On both study days, vit C was administered after the baseline
histamine challenge test and the second histamine challenge test was
carried out 1 h later. No placebo.
Randomization Not a randomized trial.
Allocation concealment Not applicable.
Blinding of participants and personnel Not blinded.
Blinding of outcome assessment Not blinded.
Drop-outs One participant out of 10 was excluded from the statistical analysis
because she had whooping cough and not the common cold.
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calculations.
In the analysis of the Bucca et al. data, linear modeling
(lm program of the R package [28]) was used to determine
whether the effect of vitamin C on the common-cold-day
could be explained by the baseline log(PC20) level values
a) on the common-cold-day or b) on the day the partici-
pant had recovered, or c) by the vitamin C effect on the
day the participant had recovered. The improvement
of model fit was assessed by the likelihood ratio test.
The vitamin C effect on the common-cold-day was
significantly explained by the baseline log(PC20) level on
the common-cold-day and by the vitamin C effect on
the day the participant had recovered. Compared withthe null model without the explanatory variables, the
addition of these two variables improved the model fit
by χ2(2 df ) = 9.1, P = .011. Since the vitamin C effect on
the common-cold-day was explained by the vitamin C
effect on the day the participant had recovered, the latter
was subtracted from the former, which gave an adjusted
vitamin C effect. In a linear model, the adjusted vitamin C
effect was significantly explained by the baseline log(PC20)
level: χ2(1 df ) = 6.2, P = .013 (Figure 1). See Additional
file 3 for the calculations.
In the Bucca et al. data, the association between the
histamine PC20 levels on the two study days separated
by a 6 week period was analyzed using the “cor.test” and
“lm” programs of the R package [28]. The influence of
Table 3 Findings of the included trials
Study Outcome P (2-tail) for
the difference
Estimate of vitamin C
effect (95% CI)
Notes
Anah et al. 1980 [27] Incidence of all asthma attacks: 0.019 RR = 0.22 (0.06 to 0.81) All asthma attacks: 9/22 and 35/19
(attacks/persons) in vit C and placebo
groups, respectively. See Additional files
2 and 3 for the calculations.
Incidence of severe and
moderate asthma attacks:
0.003 RR = 0.11 (0.02 to 0.48) Severe and moderate asthma attacks:
3/22 and 23/19 (attacks/persons) in vit C
and placebo groups, respectively. See
Additional files 2 and 3 for the calculations.
Schertling et al. 1990 [30,31] Proportion of participants who
were sensitive to histamine:
0.0005 52 percentage points
decrease (25 to 71)
The P-value was calculated from the
discordant observations: 12 were sensitive
to histamine in the placebo phase but not
in the vit C phase; 0 were sensitive to
histamine in the vit C phase but not in the
placebo phase. See Additional file 2 for the
calculations.
Asthma symptom score: 0.12 Placebo: 0.72, Vit C: 0.65 Scale 0 to 3; 0 indicates no symptoms.
The P-value was calculated by
Schertling et al. [30,31].
PEF: 0.12 Placebo: 400 L/min,
Vit C: 409 L/min
The P-value was calculated by
Schertling et al. [30,31].
Bucca et al. 1989 [25,26] Histamine PC20: 0.0003 3.2 fold increase in
PC20, (2.0 to 5.1 fold)
Vit C increased histamine PC20 geometric
mean from 7.8 to 25.1 mg/ml. See Additional
files 2 and 3 for the calculations.
Interaction between the vitamin C
effect and the common cold:
0.003 Interaction test for the vit C effect on PC20
(before/after vit C) and the presence of the
common cold (yes/no). See Additional file
2 for the calculations.
Abbreviations:
CI: Confidence Interval.
PC20: Concentration of histamine needed for a 20% FEV1 decrease.
PEF: Peak Expiratory Flow.
RR: Rate Ratio.
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log(PC20) levels on the two study days was analyzed with
linear modeling as follows. First, the baseline histamine
log(PC20) determined when the participant was suffering
from the common cold was modeled using the baseline
log(PC20) determined after the participant had recovered
as the explanatory variable. Second, the difference in the
vitamin C effects on the two study days was added to the
linear model. The comparison of these two models tested
whether vitamin C administration significantly improved
the association between the PC20 levels on the two study
days separated by 6 weeks and gave χ2(1 df ) = 9.2,
P = .0024. See Additional file 3 for the calculations.
The Bucca et al. study did not use a placebo and the
second histamine challenge test was carried out at 1 hour
after the baseline test. Therefore, studies that give infor-
mation on the role of placebo on the histamine challenge
test [7-9,33-35] and about tachyphylaxis [35-40] were
searched; see Additional file 2 for the data of two reports
[33,36]. Furthermore, one day before the first vitamin C
test day, Bucca et al. ascertained the reproducibility of
the histamine challenge test. The baseline test and the
test 1 hour later had a very close correlation (r = .96).The coefficient of variation was on average 6% for three
measurements comprising the two reproducibility day
measurements and the baseline histamine test on the
first vitamin C day [25].
The 2-tailed P-values are presented in this text.
The statistical analyses in this systematic review were
not planned in a protocol prior to the review. Instead the
statistical approaches were formulated after the data of
the selected studies became available.
Results
Three intervention studies that give information on the
effect of vitamin C on common cold-induced asthma were
identified. A total of 79 people participated in the three
trials (Table 1). The three studies are clinically heteroge-
neous and the outcomes are different. Therefore no pooled
effect can be calculated. Instead the studies are analyzed
separately. The methodological characteristics of the three
studies are described in Table 2.
The study by Anah et al. was a randomized double-blind
placebo-controlled trial with parallel groups (N = 41) [27].
The effect of 1 g/day of vitamin C on participants who had
histories of increased asthma attacks during the rainy










































Figure 1 The association between vitamin C effect and baseline histamine PC20 level on the common-cold-day. Baseline PC20 level
indicates the histamine PC20 level before vitamin C administration on the common-cold day in the Bucca et al. study [25,26]. Adjusted vitamin C
effect indicates that the vitamin C effect of the second day (after recovery at 6 wk) is subtracted from the vitamin C effect on the common-cold-day.
For example, participant #9 had a 7.45-fold increase in PC20 level on the common-cold-day and a 1.88-fold increase in PC20 level on the second day.
This gives an adjusted vitamin C effect of 3.96 (7.45/1.88). Adding the baseline histamine PC20 level to the null model increased the model fit by
χ2(1 df) = 6.2, P = .013. The horizontal dash (−) line indicates the level of vitamin C effect after recovery. The numbers indicate the identification
numbers used in Additional file 2. See the Additional file 3 for the calculations of the linear model.
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their attacks were precipitated by respiratory infections,
which started with a sore throat and a dry cough. The
14-week trial was carried out during the Nigerian rainy
season. The study recorded 35 asthma attacks in the
placebo group (n = 19), but only 9 attacks in the vitamin C
group (n = 22). Thus, vitamin C decreased the incidence
of all asthma exacerbations by 78% (Table 3). The effect
appeared even greater on those asthma exacerbations that
were classified as severe or moderate, which decreased by
89% (Table 3). Furthermore, Anah et al. reported that
there was a recurrence of asthma attacks in the vitamin C
group within 8 weeks after vitamin administration was
discontinued, though no quantitative data were published.
The study by Schertling et al. was a randomized double-
blind placebo-controlled cross-over trial conducted in the
former East Germany (N = 29) [30,31]. The effect of
5 g/day of vitamin C was studied on participants who had
a diagnosis of infection-related asthma. Schertling et al.
tested bronchial responsiveness to histamine so that
hypersensitivity was defined as increase in respiratory tract
resistance of 50% for a cumulative exposure to <1 μmol
histamine. Vitamin C decreased the proportion of partici-
pants who were sensitive to histamine by 52 percentagepoints (Table 3). The decrease in prevalence was from
91% (21/23) during the placebo phase to 39% (9/23)
during the vitamin C phase. The mean symptom scores
and PEF values were also reported and, though non-
significant, their differences were in favor of vitamin C
(Table 3).
Bucca et al. investigated the effect of a single dose 1 g
vitamin C on histamine challenge test of common cold
patients in a self-controlled study (n = 9) [25,26]. A second
pair of histamine challenge tests was carried out 6 weeks
later after the participants had recovered. When the
participants suffered from the common cold, the baseline
PC20 level was 50% lower than after they had recovered
(P = .005), which indicates that the common cold increased
bronchial sensitivity to histamine. When the participants
suffered from the common cold, vitamin C administration
caused a 3.2-fold increase in the geometric mean histamine
PC20 level in the baseline values of 7.8 to 25.1 mg/ml
(Table 3). After the participants had recovered from the
common cold 6 weeks later, vitamin C increased the PC20
level by just 1.6 fold.
A comparison between the two study days found that
there was a significant interaction between the vitamin C
effect and the presence of the common cold (P = .003),
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hypersensitivity was different between the two test days
separated by 6 weeks. Furthermore, a linear regression
analysis revealed that the difference in the vitamin C effect
between the two study days depended significantly on the
baseline histamine PC20 level determined on the common-
cold-day (Figure 1). If there are factors causing bias in the
self-controlled comparison and if the factors are constant
on both study days, they would be removed from the
calculation of the adjusted vitamin C effect, i.e., the
difference in effect between the two study days. Such
potential factors include the placebo effect and tachy-
phylaxis. The linear regression model indicated there
were no differences in the vitamin C effects between the
two study days when the baseline histamine PC20 level
was 25 mg/ml on the common-cold-day (Figure 1).
However, when the baseline PC20 level was 2 mg/ml on
the common-cold-day, the model predicted that vitamin
C administration would increase the histamine PC20 level
4.7-fold over the corresponding effect after recovery from
the cold.
In the study by Bucca et al., there was a significant
correlation between the histamine PC20 levels on the
two study days after vitamin C administration (r = 0.81,
P = .008). After vitamin C administration the geometric
means of the PC20 levels on the two days were essentially
identical: 25.1 vs. 25.7 mg/ml [25]. Before vitamin C
administration the correlation between the PC20 levels
for the two days was weak (r = 0.66, P = .054). Linear
modeling was used to determine whether the increase
in correlation caused by vitamin C administration was
statistically significant. Adding the difference between
the vitamin C effects for the two study days as a factor
to the linear model explaining the baseline PC20 levels on
the common-cold-day by the baseline PC20 levels after
recovery improved the fit of the linear model significantly
(P = .003). Consequently, the closer association between
the PC20 values after vitamin C administration cannot be
explained by random variation alone.
Bucca et al. did not use a placebo [25], and therefore
data on the possible role of placebo on the histamine
challenge test was assessed from other studies. One
study reported that the histamine sensitivity on the pla-
cebo day did not differ from the levels on the no-treatment
day (95% CI: -22% to +21%) [33]. Other studies also found
no effect of placebo on histamine sensitivity [7-9,34,35].
Another potential problem in the Bucca group’s study
design was tachyphylaxis, which indicates that a second
histamine challenge test carried out too soon after the
first test might lead to increased PC20 values. Although
this phenomenon has been reported, in one study the
increase in histamine PC20 value was less than 1.5-fold
for the second challenge test carried out at 1 hour after
the first test [36]. Other studies have found small or notachyphylaxis effects [35,37-40]. Furthermore, the close
reproducibility of the histamine challenge test in the
Bucca et al. study is also inconsistent with a substantial
tachyphylaxis effect [25]. Finally, if there is a constant
placebo effect or tachyphylaxis that would cause bias,
such effects would be eliminated from the calculation of
the adjusted vitamin C effect, i.e., the difference in effects
between the two study days. Therefore, the strong
association between the adjusted vitamin C effect and
the baseline histamine PC20 level is a further argument
against the placebo effect and the tachyphylaxis effect
(Figure 1). In conclusion, the placebo effect is not an
issue and tachyphylaxis does not explain the 3.2-fold
increase in the histamine PC20 level of common cold
patients who were administered vitamin C.
Discussion
The three identified studies give relevant information for
assessing the potential role of vitamin C on alleviating
asthma exacerbations caused by the common cold. The
studies differ substantially in their methods, participants,
settings and outcomes, yet each of them found a benefit
from vitamin C administration.
Anah et al. [27] recorded the occurrence of asthma
exacerbations, whereas Schertling et al. [30] and Bucca
et al. [25] studied bronchial sensitivity to histamine. The
common cold can lead to a transient bronchial hyper-
sensitivity, which is a characteristic feature of asthma
[7-12,25]. Challenge tests with histamine and methacho-
line have been widely used for the examinations of
asthma patients [41]. Furthermore, reducing the airway
hypersensitivity of asthmatics led to a significant reduction
in asthma exacerbations, which implies that bronchial
hypersensitivity is a clinically important measure of the
asthma severity [42].
Two of the identified studies [27,30] were randomized
double-blind placebo-controlled trials. Both studies used
patients who suffered from infection-related asthma. Anah
et al. found that vitamin C decreased the occurrence of
respiratory infection-induced asthma attacks by 78%
[27]. Schertling et al. found that vitamin C decreased the
proportion of asthma patients who suffered from bron-
chial hypersensitivity to histamine by 58 percentage
points [30]. In the Schertling group’s study, vitamin C did
not influence asthma symptoms or PEF values. However,
the number of participants in that study was small and
therefore the study had insufficient statistical power to test
the effect on these outcomes. The Anah et al. study was
carried out in Nigeria in the 1970s, and Schertling et al.
study was carried out in former East Germany in the 1980s.
Thus, those findings cannot be directly extrapolated to
Western countries in the 2010s. Nevertheless, these two
trials were methodologically strong. The highly significant
effects caused by vitamin C administration indicate a
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suffer from common cold-induced asthma exacerbations.
Bucca et al. found that vitamin C administration caused
a 3.2-fold increase in histamine PC20 levels of common
cold patients, which indicates that vitamin C decreased
bronchial hypersensitivity caused by the common cold
[25]. The effect of vitamin C was significantly smaller after
the participants had recovered from the colds. Further-
more, on the two vitamin C test days, which were separated
by 6 weeks, histamine PC20 levels correlated significantly
after vitamin C was administered, but did not do so before
its administration. This indicates that vitamin C admin-
istration was associated with a kind of normalization of
bronchial sensitivity. The study by Bucca and colleagues
is methodologically weaker than the two other studies,
but analyzing the two study days gives much strength
compared with measuring participants only on the
common-cold-day. In any case, placebo effect and tachy-
phylaxis do not readily explain the effect of vitamin C
found in the participants when they were suffering from
the common cold.
Publication bias might be a problem in the case where
a few studies have been published. However, publication
bias cannot reasonably explain the remarkably small
P-values found in each of the three studies reviewed
here. Furthermore, publication bias cannot explain findings
that are not published in the original study reports.
Therefore, publication bias cannot explain the association
between the PC20 level on the common-cold day and
the adjusted vitamin C effect (Figure 1). This systematic
review was done by one person and one person might
have a higher error rate in the extraction of data than a
group. However, only three studies are included and the
extracted data were several times compared against the
original study reports. It is unlikely that errors would have
remained. Furthermore, to increase transparency in this
systematic review, the extracted data and the calculations
are described in Additional files 2 and 3.
Asthma is a heterogeneous syndrome, an “umbrella
concept,” that comprises a collection of different pheno-
types with different underlying pathophysiologies, rather
than a single disease [43,44]. A previous meta-analysis
found that vitamin C may alleviate exercise-induced
bronchoconstriction [24] and the current study revealed
that vitamin C may alleviate common cold-induced asthma
exacerbations. It is noteworthy that both of these condi-
tions involve short-term stress, caused either by physical
exertion or by an infectious disease. Given the diverse
asthma phenotypes that exist, it is relevant to con-
sider whether vitamin C might influence other asthma
phenotypes.
In a four-month study of British asthmatics who regularly
used inhaled corticosteroids, Fogarty et al. found no effect
of 1 g/day vitamin C on the FEV1 level, on bronchialsensitivity to methacholine, or on asthma symptoms [45].
However, those authors found that the need for inhaled
corticosteroids was slightly lower in the vitamin C group
[46]. The Fogarty et al. study indicates that regular vitamin
C administration is not substantially beneficial for patients
with persistent asthma without acute problems. However,
their study does not conflict with the possibility that
vitamin C may be beneficial for pulmonary functions of
some asthmatics under certain forms of acute stress, such
as people who endure heavy physical activity or suffer
from a viral respiratory tract infection.
Evidently, more research on the role of vitamin C on
common cold-induced asthma is needed. On the other
hand, vitamin C costs only a few pennies per gram and it
is safe in gram doses [16,17,47]. Given the strong evidence
that shows that vitamin C alleviates common cold symp-
toms [14-17], and the findings of this systematic review, it
may be reasonable for asthmatic patients to test vitamin C
on an individual basis when they have exacerbations of
asthma caused by respiratory infections.Additional files
Additional file 1: Flow diagram of the literature.
Additional file 2: Extraction and analysis of data.
Additional file 3: Analysis of data: R-program printouts.Abbreviations
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